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Stents in Treatment of
Aortic Coarctation*
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Saint Louis, Missouri
Vascular stenotic lesions can be opened by balloon angioplasty
techniques, but because of elastic recoil of the vessel wall, the
vessel lumen returns to the predilation size after withdrawal of
the balloon catheter. Such recoil and vascular dissection, if any,
after balloon dilation can be circumvented by implantation of
endovascular stents. Dotter (1), in the late 1960s, suggested
this concept and implanted spiral coil-spring prostheses into
the experimentally produced peripheral artery stenotic lesions.
The stent concept and technology were dormant until the early
1980s, when the balloon-expandable and self-expanding stents
were designed and used (2). Initially, stents were used in the
treatment of peripheral arterial disease and coronary artery
stenotic lesions in adults. The technique was then extended to
the treatment of stenotic branch pulmonary arteries (3),
postoperative venous obstructions (3,4) and other congenital
and acquired stenotic lesions in children. To my knowledge,
O’Laughlin et al. (5) were the first to report use of a stent for
aortic coarctation, although the results in a 12-year-old child
were marginal. Subsequently, others (6–10) reported use of
stents for coarctation with encouraging results.
In this issue of the Journal, Ebeid et al. (11) present the
results of stent implantation in nine patients 14 to 63 years old.
Reduction in peak to peak systolic pressure gradient across the
coarctation and increase in the diameter of the coarcted
segment occurred immediately after stent placement. At a
median follow-up of 13 months, residual peak to peak systolic
pressure gradient across the stented segment remained low.
One patient required redilation of the stent. Although Ebeid et
al. state that they did not detect femoral artery problems, it is
probably a good idea to examine physiologic effects (12) or
noninvasive (13) or invasive (12) imaging of the femoral
arteries used for stent implantation to detect femoral artery
compromise or blockage. Despite this limitation, I believe that
this report supplements the previously reported limited expe-
rience with this technique. Ebeid et al. further demonstrate the
feasibility of redilation 3 years after stent placement. Finally,
they show no evidence for obstruction of the left subclavian
artery and left common carotid artery, even though the stent
spanned the origins of these vessels from the aortic arch. The
data from Ebeid et al., together with those of others (6–10),
suggest that stenting of aortic coarctation in selected patients is
a feasible and effective alternative to surgical or balloon
therapy. Several issues with regard to aortic stents are worthy
of further discussion.
Indications. The indications for stent implantation are not
clearly defined at this time. On the basis of limited experience
(6–11), the indications are hypoplasia of the isthmus or
transverse aortic arch and tortuous coarctation with malalign-
ment of the proximal with distal aortic segment, which are
difficult to treat surgically (7). Recurrent aortic coarctation or
small aneurysm after previous surgical or balloon therapy may
be another indication for implantation of stents.
Technical issues. The balloon-expandable Palmaz stent
(Johnson & Johnson) mounted on a balloon dilation catheter
usually requires a large-diameter delivery sheath for stent
implantation. Indeed, Ebeid et al. (11) used 10F to 12F
sheaths, whereas Bulbul et al. (8) utilized 12F to 14F sheaths.
It is generally recognized that arterial compromise or disrup-
tion, or both, may result after insertion of large sheaths.
Therefore, innovative use of available technology should be
incorporated into our practice such that smaller sized sheaths
may be utilized for stent implantation (14,15). Stents may be
mounted on an 8- or 10-mm Olbert balloon that can be
introduced through an 8F or 9F sheath for initial deployment,
which can be expanded to the required size with a larger
balloon (15). More recently, the manufacturer of the Palmaz
stent has designed balloons (up to 15-mm diameter) carried on
smaller catheter shafts on which the stents could be mounted
and delivered to the implantation site by 8F sheaths. It is
important to seriously consider reducing the delivery sheath
size because of femoral artery compromise (12); even in adults,
6F guide catheters produce less arterial damage than 7F and
8F catheters (16).
Age at implantation. Ebeid et al. (11) and Balbul et al. (8)
implanted aortic stents in older children and adults, whereas
other workers (6,7,10) used stents in infants and younger
children. Limiting the use to older subjects is justified (8,11)
because of limited evidence for the feasibility of reexpansion of
the stents at a later date. However, it may be necessary to
implant aortic stents in younger children. Therefore, the
feasibility of such use should be explored. The feasibility of
reexpansion of the stents in animal models (17–19), pulmonary
artery stents in children (20) and aortic stents in adolescent
and adult subjects (8,11) is encouraging, although reported
aortic dissection in two of seven redilations of aortic stents in
animal models (21) is of concern.
Other methods to resolve this problem should also be
considered. Modification of the stent by creating an “open-
ring” stent has made it possible to overdilate the stent in
animal models (22). Clinical trials of this type of modification
in young children are needed to demonstrate the usefulness of
this technique. Another method by which this problem can be
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tackled is to use biodegradable stents (23). Several types of
materials and designs are in the process of testing in animal
models (23) and are soon likely to be available for clinical trials
in human subjects.
Other issues. Longitudinal rigidity. The Palmaz stent, the
most commonly used stent in the pediatric patient, is very rigid
and may be difficult to implant into tortuous vessels, or the
stent may cause disruption of the vessel wall (7). This problem
may be circumvented by introducing a bridging articulation
(24) and development of a multilink system (25). Alternatively,
flexibility could be improved by using a single-filament con-
struction of the stent.
Intimal proliferation. Varying degrees of neointimal growth
have been reported and are more prevalent with self-
expandable stents such as the Wallstent than the Palmaz stent
(26). Therefore, it was postulated that external radial forces
may contribute to the proliferative response. Intimal growth
has also been observed at the ends of the stent, especially when
a vessel–stent size mismatch exists and at the site of a previous
stenosis. Neointimal proliferation may cause significant ob-
struction, especially in small vessels. Avoidance of factors likely
to cause excessive neointimal growth should be undertaken.
Local delivery of heparin or dexamethasone may reduce
intimal proliferation but is at present not available for the
clinical setting under consideration.
Obstruction of branch vessels. It is generally believed that
the branch vessels that arise perpendicular to the axis of the
stent (aorta) remain patent after stent deployment. In animal
models, the spinal arteries were found to be patent after stent
placement in the aorta (27), similar to demonstrated patency
of side branches from the coronary arteries after stenting (28).
Observations in human subjects confirm the patency of the
side vessels after aortic stenting (7). In one of the subjects of
Ebeid et al. (11), the stent covered the mouth of the left
subclavian artery and part of the left common carotid artery
origin at initial implantation. Angiography 3 years later
showed unrestricted flow to both of these vessels. Although
the available data are encouraging, because of the limited
nature of observations, we should continue to gather
follow-up data on the patency of branch vessels after aortic
implantation of stents.
Conclusions. Although experience is limited, stents appear
to be useful adjuncts to balloon angioplasty in the treatment of
isthmic hypoplasia and tortuous coarcted segments. They may
also have a useful role in the management of aortic disruptions
or aneurysms after previous balloon or surgical therapy. Be-
cause of the need for insertion of large stent delivery sheaths
into femoral artery, arterial compromise is likely to be signif-
icant. This may improve with the miniaturization of stent
delivery systems, which is currently taking place. Implantation
of stents in older children and adults in whom the aorta size
has attained adult size is not problematic, although such may
be problematic in infants and young children, whose aorta will
grow with time unless the stents can be reexpanded. Alterna-
tively, biodegradable stents, when they become available for
clinical use, may help resolve this issue. Stent-deployed aortic
segment is noncompliant and nonpulsatile. Whether this non-
compliance adversely affects blood pressure regulation remains
to be seen. With these reservations in mind, it is prudent to
limit use of stents in patients with aortic coarctation for whom
there are no other effective and safe alternative modes of
therapy.
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